Work

ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer

Year: 2020

Type: article

Source: Cancer Letters

DOI: 10.1016/j.canlet.2019.12.037

Authors: Mark Barok, Vadim Le Joncour, Ana Martins, Jorma Isola, Marko Salmikangas, Pirjo Laakkonen, Heikki Joensuu

Institutions: University of Helsinki, Tampere University, University of Tampere, HiLIFE – Elämäntieteiden Instituutti, Helsinki University Hospital

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Academy of Finland, Jane ja Aatos Erkon Säätiö, Sigrid Juséliuksen Säätiö, Syöpäjärjestöt, K. Albin Johanssons Stiftelse

OpenAlex ID: W2997835015

FWCI: 3.069

Cites: 29

Cited by: 81

Related to: 10